Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which are designed for targeting retinoblastoma (RB) protein phosphorylation and thereby block cancer cell growth, have been approved by the FDA as frontline targeted therapies for hormone receptor-positive (HR+), HER2-negative breast cancer. This evidence concerns the gene RB1 and cancer.